Report

Global Bovine Respiratory Disease Treatment Market Size study & Forecast, by Material Treatment Type, Disease Type, and Regional Analysis, 2022-2029

  • Publish Date: Feb,2023
  • Report ID: 3-2-1752
  • Page : 200
  • Report Type : PDF (Email)
Global Bovine Respiratory Disease Treatment Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2029. Bovine Respiratory Disease Treatment refers to the common diseases occur to cattle globally. It includes infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD), and parainfluenza type-3 virus (PI-3). The Bovine Respiratory Disease Treatment market is expanding because of factors such as the growing consumption of beef and rising incidences of bovine respiratory diseases

According to the article published in September 2022, titled "World Beef Consumption: Ranking of Countries (USDA)," global beef consumption stood at 147.34 billion pounds in 2020. The United States consumed the most beef in 2020, followed by China, the European Union, Brazil, and India.

Whereas, rising cases of Diphtheria and growing R&D activities by market players create lucrative opportunities for the market. However, the lack of skilled veterinarians hampers the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Bovine Respiratory Disease Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the increasing production and consumption of bovine meat and rising cases of BRD, and increasing awareness of bovine respiratory treatment Whereas North America is expected to grow significantly during the forecast period, owing to factors such as increasing technological advances in products to monitor BRD and growing penetration of market players etc. in the forecast period

Major market players included in this report are:

Bimeda

Boehringer Ingelheim GmbH

Ceva

Elanco

Krka UK Ltd

Merial

Merck & Co. Inc.

Vetoquinol

Virbac

Zoetis Inc.

Recent Developments in the Market:

In August 2022, the researchers and bioinformatics core of University of Lethbridge's Southern Alberta Genome Science Centre (SAGSC) collaborated with scientists at agriculture and agri-food Canada with the aim to develop viable solutions to mitigate bovine respiratory diseases.
In March 2022, Merck Animal Health, a division of Merck & Co., Inc., known as MSD Animal Health outside the United States and Canada, received FDA approval for AROVYN (tulathromycin injection) - a broad-spectrum, prescription antibiotic that treats the major organisms associated with bovine respiratory disease (BRD), foot rot, and pinkeye.
Global Bovine Respiratory Disease Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Treatment, Disease, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:

Vaccines,

Antibiotics,

NSAIDs,

Immunomodulators,

Other Treatment Types

By Disease:

Lower Respiratory Tract Infections,

Upper Respiratory Tract Infections,

Diphtheria

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World